Cargando…
Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological target. The mechanisms of adaptation to long-term silencing of AKT isof...
Autores principales: | Arasanz, Hugo, Hernández, Carlos, Bocanegra, Ana, Chocarro, Luisa, Zuazo, Miren, Gato, Maria, Ausin, Karina, Santamaría, Enrique, Fernández-Irigoyen, Joaquín, Fernandez, Gonzalo, Santamaria, Eva, Rodríguez, Carlos, Blanco-Luquin, Idoia, Vera, Ruth, Escors, David, Kochan, Grazyna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464748/ https://www.ncbi.nlm.nih.gov/pubmed/32764385 http://dx.doi.org/10.3390/cancers12082181 |
Ejemplares similares
-
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020) -
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020) -
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020) -
A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets
por: Blanco, Ester, et al.
Publicado: (2021) -
Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)